Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
Cureus ; 16(6): e62361, 2024 Jun.
Article in English | MEDLINE | ID: mdl-39006718

ABSTRACT

Pyoderma gangrenosum (PG) is a rare and persistent neutrophilic dermatosis with an unknown cause. The condition typically manifests clinically as a pustule or plaque that quickly evolves into a necrotic ulcer with undermined violet-colored margins. A surgical debridement might worsen the disease due to the pathergy phenomenon. This case report presents a 48-year-old woman who underwent a late breast reconstruction with a transverse rectus abdominis myocutaneous flap and was subsequently diagnosed with PG. The report details the delays in the diagnosis and management of the disease, providing a comprehensive account of the course of events.

2.
Cureus ; 14(8): e28180, 2022 Aug.
Article in English | MEDLINE | ID: mdl-36148205

ABSTRACT

A 35-year-old woman with a history of polyacrylamide hydrogel filler injection was referred with a fluctuating facial abscess after decayed tooth extraction. MRI imaging confirmed the diagnosis of an abscess. After appropriate treatment, the patient healed with a little hyperpigmentation and deformity in the zygomaticotemporal area. Although polyacrylamide hydrogel filler injection is considered non-toxic, non-immunogenic, and biocompatible; as a permanent material, physicians should be aware of the risk of its late complications such as late infections. In addition to antiseptic measures, antibiotic prophylaxis may be necessary before the procedures which have a risk of bacteremia and close to the permanent filler location.

3.
Acta Neuropathol Commun ; 9(1): 67, 2021 04 14.
Article in English | MEDLINE | ID: mdl-33853689

ABSTRACT

One of the most prominent features of glioblastoma (GBM) is hyper-vascularization. Bone marrow-derived macrophages are actively recruited to the tumor and referred to as glioma-associated macrophages (GAMs) which are thought to provide a critical role in tumor neo-vascularization. However, the mechanisms by which GAMs regulate endothelial cells (ECs) in the process of tumor vascularization and response to anti-angiogenic therapy (AATx) is not well-understood. Here we show that GBM cells secrete IL-8 and CCL2 which stimulate GAMs to produce TNFα. Subsequently, TNFα induces a distinct gene expression signature of activated ECs including VCAM-1, ICAM-1, CXCL5, and CXCL10. Inhibition of TNFα blocks GAM-induced EC activation both in vitro and in vivo and improve survival in mouse glioma models. Importantly we show that high TNFα expression predicts worse response to Bevacizumab in GBM patients. We further demonstrated in mouse model that treatment with B20.4.1.1, the mouse analog of Bevacizumab, increased macrophage recruitment to the tumor area and correlated with upregulated TNFα expression in GAMs and increased EC activation, which may be responsible for the failure of AATx in GBMs. These results suggest TNFα is a novel therapeutic that may reverse resistance to AATx. Future clinical studies should be aimed at inhibiting TNFα as a concurrent therapy in GBMs.


Subject(s)
Brain Neoplasms/pathology , Drug Resistance, Neoplasm/physiology , Glioma/pathology , Macrophages/metabolism , Neovascularization, Pathologic/metabolism , Tumor Necrosis Factor-alpha/metabolism , Angiogenesis Inhibitors/pharmacology , Animals , Brain Neoplasms/metabolism , Endothelial Cells/metabolism , Glioma/metabolism , Humans , Mice , Neovascularization, Pathologic/pathology , Xenograft Model Antitumor Assays
4.
Blood Purif ; 46(1): 34-47, 2018.
Article in English | MEDLINE | ID: mdl-29649794

ABSTRACT

Volume overload is an important, may be the foremost, independent prognostic factor determining the outcome of hemodialysis patients. Therefore, it is crucial to measure fluid status of these patients and avoid volume overload. This review aims to evaluate volume overload, its effects on patients with renal diseases and current methodologies measuring volume status in the body. These techniques will be first classified as clinical evaluation and non-clinical and/or instrumental techniques, which includes biomarkers, ultrasonography, relative blood volume monitoring, bioimpedance, echocardiography, pulmonary artery catheterization, esophageal and/or suprasternal Doppler, and blood viscosity. Advantages and limitations of these different techniques will be reviewed extensively by comparing each other. At last, insights gained from this review can highlight the future prospects in this active area of research.


Subject(s)
Blood Volume , Renal Dialysis/methods , Water-Electrolyte Imbalance/diagnosis , Electric Impedance , Humans , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Renal Dialysis/adverse effects , Ultrasonography , Water-Electrolyte Imbalance/diagnostic imaging
5.
Oncotarget ; 7(35): 56431-56446, 2016 Aug 30.
Article in English | MEDLINE | ID: mdl-27421140

ABSTRACT

The RNAse III endonuclease DICER is a key regulator of microRNA (miRNA) biogenesis and is frequently decreased in a variety of malignancies. We characterized the role of DICER in glioblastoma (GB), specifically demonstrating its effects on the ability of glioma stem-like cells (GSCs) to form tumors in a mouse model of GB. DICER silencing in GSCs reduced their stem cell characteristics, while tumors arising from these cells were more aggressive, larger in volume, and displayed a higher proliferation index and lineage differentiation. The resulting tumors, however, were more sensitive to radiation treatment. Our results demonstrate that DICER silencing enhances the tumorigenic potential of GSCs, providing a platform for analysis of specific relevant miRNAs and development of potentially novel therapies against GB.


Subject(s)
Brain Neoplasms/genetics , DEAD-box RNA Helicases/metabolism , Gene Expression Regulation, Neoplastic , Glioblastoma/genetics , MicroRNAs/genetics , Neoplastic Stem Cells/metabolism , Ribonuclease III/metabolism , Animals , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/pathology , Brain Neoplasms/radiotherapy , Carcinogenesis/genetics , Cell Differentiation/genetics , Cell Line, Tumor , Cell Proliferation/genetics , DEAD-box RNA Helicases/genetics , Gene Knockdown Techniques , Glioblastoma/diagnostic imaging , Glioblastoma/pathology , Glioblastoma/radiotherapy , Humans , Magnetic Resonance Imaging , Mice , Mice, Inbred NOD , Mice, SCID , RNA Interference , RNA, Small Interfering , Ribonuclease III/genetics , Xenograft Model Antitumor Assays
6.
CNS Oncol ; 5(3): 159-73, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27230973

ABSTRACT

Tumors of the CNS are composed of a complex mixture of neoplastic cells, in addition to vascular, inflammatory and stromal components. Similar to most other tumors, brain tumors contain a heterogeneous population of cells that are found at different stages of differentiation. The cancer stem cell hypothesis suggests that all tumors are composed of subpopulation of cells with stem-like properties, which are capable of self-renewal, display resistance to therapy and lead to tumor recurrence. One of the most important transcription factors that regulate cancer stem cell properties is SOX2. In this review, we focus on SOX2 and the complex network of signaling molecules and transcription factors that regulate its expression and function in brain tumor initiating cells. We also highlight important findings in the literature about the role of SOX2 in glioblastoma and medulloblastoma, where it has been more extensively studied.


Subject(s)
Brain Neoplasms/metabolism , SOXB1 Transcription Factors/metabolism , Humans , SOXB1 Transcription Factors/genetics , Signal Transduction/physiology
SELECTION OF CITATIONS
SEARCH DETAIL